Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 -

- Cash runway into the second quarter of 2026 -

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update.

Read more at globenewswire.com